8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K

___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2017

___________________

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

___________________

Ireland(State or Other Jurisdiction of Incorporation)		000-28508 (Commission File Number)		98-1341933 (I.R.S. Employer Identification No.)
	Block 10-1 Blanchardstown Corporate Park, Ballycoolin Dublin 15, Ireland (Address of Principal Executive Offices)		Not Applicable (Zip Code)

Registrant's telephone number, including area code: +353 1 485 1200

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.05Costs Associated with Exit or Disposal Activities.

On March 30, 2017, Avadel Pharmaceuticals plc (the "Company") issued a press release announcing a plan to reduce its headcount in France by approximately 50 people.  This reduction is an effort to align the Company's cost structure with its ongoing and future planned projects.  This action does not affect the allocation of resources to its REST-ON Phase III clinical trial or any other important pipeline initiatives.  Subject to French regulatory requirements, the Company expects the reduction to be substantially completed by the end of July 2017 and to incur related employee severance, benefits and other costs of approximately $2.5 to $4.0 million.  Once fully implemented, the Company anticipates annual costs savings of approximately $3.5 to $4.0 million.

A copy of the Company's March 30, 2017 press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

99.1  

 Press release of Avadel Pharmaceuticals plc dated March 30, 2017.
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVADEL PHARMACEUTICALS PLC

By:/s/ Phillandas T. Thompson

Phillandas T. Thompson

Senior Vice President, General Counsel and Corporate Secretary

Date: March 31, 2017

Exhibit Index

99.1 

 Press release of Avadel Pharmaceuticals plc dated March 30, 2017.
 

EX-99.1

Exhibit 99.1

Avadel Pharmaceuticals  Announces Planned Reduction of French Workforce

Dublin, Ireland – 30 March 2017 – Avadel Pharmaceuticals plc (NASDAQ: AVDL), today announced a plan to reduce its headcount in France by approximately 50 people. This reduction is an effort to align the Company's cost structure with its ongoing and future planned projects. This action does not affect the allocation of resources to its REST-ON Phase III clinical trial or any other important pipeline initiatives.

Subject to French regulatory requirements, the Company expects the reduction to be substantially completed by end of July 2017 and to incur related employee severance, benefits and other costs of approximately $2.5 to $4.0 million.  Once fully implemented, the company anticipates annual costs savings of approximately $3.5 to $4.0 million.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel currently markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Safe Harbor: This release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and the negative of these and similar expressions generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Avadel's control and could cause actual results to differ materially from the results contemplated in such forward-looking statements. These risks, uncertainties and contingencies include the risks relating to: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz®,Vazculep® and Akovaz® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such product and apply for FDA approval of such product before us; our dependence on the performance of third parties in partnerships or strategic alliances for the commercialization of some of our products; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; our dependence on key personnel to execute our business plan; the amount of additional costs we will incur to comply with U.S. securities laws as a result of our ceasing to qualify as a foreign private issuer; and the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2015, all of which filings are also available on the Company's website. Avadel undertakes no obligation to update its forward-looking statements as a result of new information, future events or otherwise, except as required by law.

*******

Contacts:	Michael F. Kanan Chief Financial Officer Phone:(636) 449-1844 E-mail:  mkanan@avadel.com
	Lauren Stival Sr. Director, Investor Relations and Corporate Communications Phone:  (636) 449-5866 Email:  Istival@avadel.com